Immunotherapy of Prostate Cancer: Facts and Hopes
Tóm tắt
In the last few years, immunotherapy has become an important cancer treatment modality, and although the principles of immunotherapy have evolved over many decades, the FDA approvals of sipuleucel-T and ipilimumab began a new wave in immuno-oncology. Despite the current enthusiasm, it is unlikely that any of the immunotherapeutics alone can dramatically change prostate cancer outcomes, but combination strategies are more promising and provide a reason for optimism. Several completed and ongoing studies have shown that the combination of cancer vaccines or checkpoint inhibitors with different immunotherapeutic agents, hormonal therapy (enzalutamide), radiotherapy (radium 223), DNA-damaging agents (olaparib), or chemotherapy (docetaxel) can enhance immune responses and induce more dramatic, long-lasting clinical responses without significant toxicity. The goal of prostate cancer immunotherapy does not have to be complete eradication of advanced disease but rather the return to an immunologic equilibrium with an indolent disease state. In addition to determining the optimal combination of treatment regimens, efforts are also ongoing to discover biomarkers of immune response. With such concerted efforts, the future of immunotherapy in prostate cancer looks brighter than ever. Clin Cancer Res; 23(22); 6764–70. ©2017 AACR.
Từ khóa
Tài liệu tham khảo
Drake, 2010, Prostate cancer as a model for tumour immunotherapy, Nat Rev Immunol, 10, 580, 10.1038/nri2817
Drake, 2006, Mechanisms of immune evasion by tumors, Adv Immunol, 90, 51, 10.1016/S0065-2776(06)90002-9
Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294
Stein, 2011, Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy, Clin Cancer Res, 17, 907, 10.1158/1078-0432.CCR-10-1762
Drake, 2014, The potential role of antigen spread in immunotherapy for prostate cancer, Clin Adv Hematol Oncol, 12, 332
McNeel, 2016, The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of prostate carcinoma, J Immunother Cancer, 4, 92, 10.1186/s40425-016-0198-x
Mahoney, 2014, Prognostic and predictive markers for the new immunotherapies, Oncology, 28, 39
Gajewski, 2015, The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment, Semin Oncol, 42, 663, 10.1053/j.seminoncol.2015.05.011
Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213
Thompson, 2004, Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target, Proc Natl Acad Sci U S A, 101, 17174, 10.1073/pnas.0406351101
Beer, 2017, Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer, J Clin Oncol, 35, 40, 10.1200/JCO.2016.69.1584
Kwon, 2014, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184–043): a multicentre, randomised, double-blind, phase 3 trial, Lancet Oncol, 15, 700, 10.1016/S1470-2045(14)70189-5
Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690
Hansen, 2016, Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study, Ann Oncol, 27, 725PD, 10.1093/annonc/mdw372.09
Martin, 2015, Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance, Prostate Cancer Prostatic Dis, 18, 325, 10.1038/pcan.2015.39
Pritchard, 2014, Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer, Nat Commun, 5, 4988, 10.1038/ncomms5988
Chen, 2001, Defects of DNA mismatch repair in human prostate cancer, Cancer Res, 61, 4112
Gulley, 2014, Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer, Cancer Immunol Res, 2, 133, 10.1158/2326-6066.CIR-13-0108
Kantoff, 2010, Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer, J Clin Oncol, 28, 1099, 10.1200/JCO.2009.25.0597
Kantoff, 2017, Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer, J Clin Oncol, 35, 124, 10.1200/JCO.2016.69.7748
Podrazil, 2015, Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer, Oncotarget, 6, 18192, 10.18632/oncotarget.4145
Rojas-Martinez, 2013, Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer, Cancer Gene Ther, 20, 642, 10.1038/cgt.2013.56
Hinrichs, 2014, Exploiting the curative potential of adoptive T-cell therapy for cancer, Immunol Rev, 257, 56, 10.1111/imr.12132
Slovin, 2012, Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells, J Clin Oncol, 30, abstr TPS4700-TPS, 10.1200/jco.2012.30.15_suppl.tps4700
Farkona, 2016, Cancer immunotherapy: the beginning of the end of cancer?, BMC Med, 14, 73, 10.1186/s12916-016-0623-5
O'Sullivan Coyne, 2014, Nivolumab: promising survival signal coupled with limited toxicity raises expectations, J Clin Oncol, 32, 986, 10.1200/JCO.2013.54.5996
Sutherland, 2005, Activation of thymic regeneration in mice and humans following androgen blockade, J Immunol, 175, 2741, 10.4049/jimmunol.175.4.2741
Drake, 2005, Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen, Cancer Cell, 7, 239, 10.1016/j.ccr.2005.01.027
Mercader, 2001, T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer, Proc Natl Acad Sci U S A, 98, 14565, 10.1073/pnas.251140998
Arlen, 2005, Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer, J Urol, 174, 539, 10.1097/01.ju.0000165159.33772.5b
Ardiani, 2013, Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model, Clin Cancer Res, 19, 6205, 10.1158/1078-0432.CCR-13-1026
Bishop, 2015, PD-L1 is highly expressed in Enzalutamide resistant prostate cancer, Oncotarget, 6, 234, 10.18632/oncotarget.2703
Graff, 2016, Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer, Oncotarget, 7, 52810, 10.18632/oncotarget.10547
Hodge, 2013, Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death, Int J Cancer, 133, 624, 10.1002/ijc.28070
Kodumudi, 2010, A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers, Clin Cancer Res, 16, 4583, 10.1158/1078-0432.CCR-10-0733
Finkelstein, 2015, Combining immunotherapy and radiation for prostate cancer, Clin Genitourin Cancer, 13, 1, 10.1016/j.clgc.2014.09.001
Heery, 2016, Samarium-153-EDTMP (Quadramet(R)) with or without vaccine in metastatic castration-resistant prostate cancer: a randomized Phase 2 trial, Oncotarget, 7, 69014, 10.18632/oncotarget.10883
Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755
Malamas, 2016, Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation, Oncotarget, 7, 86937, 10.18632/oncotarget.13520
Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144
Higuchi, 2015, CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer, Cancer Immunol Res, 3, 1257, 10.1158/2326-6066.CIR-15-0044
Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859
Karzai, 2017, A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 35, abstr 162, 10.1200/JCO.2017.35.6_suppl.162
Schiewer, 2014, Transcriptional roles of PARP1 in cancer, Mol Cancer Res, 12, 1069, 10.1158/1541-7786.MCR-13-0672
Boehm, 2010, Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations, Cancer Immunol Immunother, 59, 397, 10.1007/s00262-009-0759-7
Fu, 2014, Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors, Cancer Res, 74, 4042, 10.1158/0008-5472.CAN-13-2685
Soares, 2015, PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors, J Immunother, 38, 1, 10.1097/CJI.0000000000000062
Fong, 2014, Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer, J Natl Cancer Inst, 106, 10.1093/jnci/dju268
Buchbinder, 2016, CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition, Am J Clin Oncol, 39, 98, 10.1097/COC.0000000000000239
van den Eertwegh, 2012, Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial, Lancet Oncol, 13, 509, 10.1016/S1470-2045(12)70007-4
Madan, 2012, Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial, Lancet Oncol, 13, 501, 10.1016/S1470-2045(12)70006-2
Madan, 2012, Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial, Lancet Oncol, 13, 501, 10.1016/S1470-2045(12)70006-2